Brain Tumor Committee

Purpose

The NRG Brain Tumor Committee’s charge is to pursue clinical research to better the survival and survivorship of patients with primary and secondary tumors of the central nervous system. Their focus areas are metastatic disease to the central nervous system, primary glial tumors, and additional brain neoplasms such as meningioma, primary central nervous system lymphoma, and others.  Our primary research priorities are to identify strategies to improve survival, maintain quality of life and cognitive function, investigate and provide optional palliative strategies, test and evaluate novel targeted and therapeutic strategies, and pursue combinatorial therapies. Overarching goals of the committee include: identifying the best approaches to manage brain metastases; identifying approaches to lengthen survival for patients with malignant glioma; identifying and ameliorating factors responsible for toxicities, cognitive decline, and reduction in quality of life for patient with longer survival; and, identifying the best approaches to maximize local control and enhance cure for locally recurrent tumors. This committee meets monthly via teleconference and in-person at the NRG Semiannual Meetings.

Brain Tumor Committee Leadership

Chair

Minesh Mehta, MD

Vice Chair

Arnab Chakravarti, MD

Vice Chair

Mark Gilbert, MD

Vice Chair

Michael Vogelbaum, MD, PhD
Working Groups

IDHwt Glioma

IDHmut Glioma

Mets

Translational Science Brain Tumor Working Group

Chair

Arnab Chakravarti, MD

Core Committee Members

Core Committee Members

  • Manmeet Ahluwalia
  • Ken Aldape
  • Drexell Hunter Boggs
  • Paul D. Brown
  • Stuart Burri
  • Jennifer E. Cahill
  • Arnab Chakravarti 
  • Michael Chan
  • Prakash Chinnaiyan
  • Mark Gilbert
  • Vinai Gondi*
  • Matthew Hall
  • Jona Hattangadi-Gluth
  • Virginia B. Hill
  • Fabio Iwamoto
  • Melin J. Khandekar
  • Michelle Kim
  • Jonathan Knisely
  • Rupesh Kotecha
  • Andrew Lassman
  • Rimas Lukas
  • Shearwood McClelland III
  • Minesh Mehta 
  • Mark Mishra
  • Yazmin Odia 
  • Joshua Palmer
  • Vinay Puduvalli
  • C. Leland Rogers
  • Scott Soltys
  • Paul Sperduto
  • Jason Tharp*
  • Theresa Thomas
  • Daniel Trifiletti
  • Christina Tsien
  • Yoshie Umemura*           
  • Michael Vogelbaum
  • Tony J.C. Wang
  • Jeffrey S. Wefel 
  • Jonathan T. Yang

General Committee Members

  • Jes Alexander
  • Hani Ashamalla
  • Albert Attia
  • James Battiste
  • Sasha Beyer
  • Nicholas Blondin
  • Deborah Blumenthal
  • Daniela Bota
  • Joseph Bovi
  • Steve Braustein
  • Andrew Brenner
  • Daniel Cahill
  • Arnab Chakravarti 
  • Serah Choi
  • Yunfeng Cui
  • Cristina DeCesaris
  • Alexandra N. De Leo 
  • Mahua Dey
  • Aidnag Diaz
  • Michael Dominello
  • Bently Doonan
  • Nichole Fisher
  • John Flickinger
  • Matthew Gallitto 
  • Na Tosha Gatson
  • Mark Gilbert 
  • Jon Glass
  • Vinai Gondi
  • Sharad Goyal
  • Matthew M. Grabowski
  • Sean Grimm
  • Christian Grommes
  • Shalina Gupta-Burt
  • Jona Hattangadi-Gluth
  • Grant Hunter
  • Vikram Jairam
  • Seok-Gu Kang
  • William R. Kennedy
  • Osaama Hassan Khan
  • Deepak Khuntia
  • Connor J. Kinslow
  • Roman Kowalchuk
  • Ryan D. Kraus
  • Timothy Kruser
  • Eric Lehrer
  • Jian Yi Li
  • Robert Liebross
  • Christine Lu-Emerson
  • Raymond M. Luke
  • Sean S. Mahase
  • Rachna Malani
  • Mark Malkin
  • Laurence Masson-Cote
  • Adrianna H. Masters
  • Minesh Mehta 
  • Eric A. Mellon
  • Muhammad Altaf Memon
  • Faina Nakhlis
  • Mansoor Nasim
  • Antonio Omuro
  • Shiby Paul
  • Haley Perlow
  • Richard Peterson
  • Huong Pham
  • Luke R.G. Pike
  • Paula Rauschkolb
  • Raju Raval
  • Kristin Redmond
  • Benjamin J. Rich
  • Charlotte I. Rivers
  • Ian Robins
  • Isabel Arrillaga-Romany
  • David Routman
  • Michael Rutenberg
  • Sean Sachdev
  • Anurag Saraf
  • Christopher Schultz
  • Soma Sengupta
  • Nawal Shaikh
  • Rohil Shekher
  • Colette J. Shen
  • Wenyin Shi
  • Kevin R. Shiue
  • Hui-Kuo Shu
  • Raj Singh
  • Lindsey Sloan
  • Ashok Srinivasan
  • John Suh
  • Ashley Sumrall
  • Jason Tharp
  • Leonard Tuanquin
  • Scott Turner
  • Kenneth Usuki
  • Prashant Vempati
  • Michael Vogelbaum 
  • Kyle Wang
  • Zabi Wardak
  • Fangfang Yin
  • Michael Yu
  • Jim Zhong
  • Jay-Jiguang Zhu
  • Andrew H. Zureick

Committee Liaisons

Early Career Investigator Liaisons

  • Vinai Gondi, MD
  • Yoshie Umemura, MD

Patient Advocate Liaison

  • Jason Tharp
Reset all column filters
Study Title Status Phase Disease Category Disease Site
RTOG-0424

A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High Risk Low-Grade Gliomas

 Terminated II Brain [BN] Lower Grade Glioma

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.